Rosemarie Marchan

Rosemarie Marchan serves as Group Leader of the Cell Metabolism Research Group at the Leibniz Research Centre for Working Environment and Human Factors (IfADo) in Dortmund, Germany, within the Department of Toxicology under Prof. Dr. Jan G. Hengstler. She has held this leadership position since January 2018, following seven years as a Junior Group Leader at the same institution from 2010-2017. Her research bridges toxicology and cancer biology through metabolic investigations.

• PhD in Toxicology, University of Rochester Medical Centre, USA (2008)
• M.Sc. in Toxicology, University of Rochester Medical Centre, USA (2005)
• B.Sc. in Environmental Sciences, North Carolina Central University, USA (2002)
• B.Sc. in Biology, North Carolina Central University, USA (2002)

Dr. Marchan's research program centers on cellular metabolism in cancer development and progression, with particular expertise in choline metabolism pathways. Her laboratory investigates how metabolic alterations, especially involving the glycerophosphodiesterase EDI3, influence tumor behavior and treatment resistance. Using sophisticated tumor models and metabolomics approaches, her work identifies potential metabolic vulnerabilities in cancer cells that could serve as therapeutic targets. The research has significant implications for understanding breast cancer metastasis and developing novel treatment strategies.

Analysis of Dr. Marchan's recent publication record reveals a focused trajectory in cancer metabolism research, particularly examining choline and glutathione pathways in tumor progression. Her work increasingly integrates multi-omics approaches with functional validation in advanced tumor models. A significant portion of her current research investigates EDI3's role in breast cancer metastasis and therapy resistance, with potential clinical applications for overcoming treatment failure in HER2-positive breast cancer.

While specific awards aren't detailed in the available information, Dr. Marchan's consistent publication record in high-impact journals reflects recognition within her scientific community. Her editorial contributions to Archiv für Toxikologie on topics like Nrf2 signaling and nanotoxicology demonstrate her standing as a thought leader in toxicology.

As Group Leader, Dr. Marchan oversees research operations and likely mentors junior scientists and postdoctoral researchers within her Cell Metabolism unit. Her extensive publication history suggests successful acquisition of competitive research funding, though specific grant details aren't provided in the source material. The collaborative nature of her publications, frequently involving multiple institutional partners, indicates strong networking within the toxicology and cancer research communities.

The Cell Metabolism Research Group operates within IfADo's Department of Toxicology, utilizing advanced methodologies including metabolomics, gene expression analysis, and sophisticated mouse models of cancer. The group's work connects basic metabolic research with translational applications, particularly in understanding how metabolic alterations drive tumor progression and therapy resistance in breast cancer.